| 前收市價 | 47.27 |
| 開市 | 44.12 |
| 買盤 | 55.20 |
| 賣出價 | 62.80 |
| 拍板 | 980.00 |
| 到期日 | 2024-06-21 |
| 今日波幅 | 44.12 - 54.80 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 170 |
Investor's Business DailyWhy It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
There hasn't been a new COPD treatment in years. But Regeneron stock analysts are closely watching a pair of key FDA decisions.
Investor's Business DailyWhy Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club
Regeneron stock joined the 1,000-club this month as enthusiasm grows for its blockbuster drug, Dupixent, in COPD treatment.
ZacksRegeneron (REGN), SNY Win FDA Nod for Kevzara Label Expansion
The FDA approves label expansion of Regeneron (REGN) and Sanofi's Kevzara for the treatment of polyarticular juvenile idiopathic arthritis.
